NIRAPARIB AND ABIRATERONE ACETATE PLUS PREDNISONE TO IMPROVE CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HRR ALTERATIONS
The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median r...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ZHANG, Ke THOMAS, Shibu DEL CORRAL, Adam A LOPEZ-GITLITZ, Angela Mennicke WANG, Guilin URTISHAK, Karen Ann HUTNICK, Natalie A GORMLEY, Michael P LI, Susan Xuemei FRANCIS, Peter |
| description | The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median radiographic progression-free survival (rPFS).
La présente invention concerne du niraparib et de l'acétate d'abiratérone, plus de la prednisone ou de la prednisolone ; pour une utilisation dans un procédé d'amélioration de l'efficacité du traitement du cancer de la prostate résistant à la castration métastatique (CPRCm) chez un patient présentant des anomalies de réparation de l'ADN, en particulier pour améliorer la survie sans progression radiographique (SSPr) médiane. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2023148345A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2023148345A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2023148345A13</originalsourceid><addsrcrecordid>eNqNjsGKAkEMROfiQVz_IeB5YHUUvGZilgnMpJvuqEcRaU_LruD-0f6ocfADPFWlKF5qWv2rJIyYpAXUHWDrp3EKyoDE5h5iv88QE-9U8jO3ADLEFA4M1IsKYQ9hbxQGziAKEU1YLcNRrIPBIdk5QkBunC5B68RZPFVzcMjjG0IlTuOKLrn2PmMs549qcj1_38v8pbNq8cVGXV1uv6dyv50v5af8nY5h9blqlutts97gsnmv9QC1HEdF</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>NIRAPARIB AND ABIRATERONE ACETATE PLUS PREDNISONE TO IMPROVE CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HRR ALTERATIONS</title><source>esp@cenet</source><creator>ZHANG, Ke ; THOMAS, Shibu ; DEL CORRAL, Adam A ; LOPEZ-GITLITZ, Angela Mennicke ; WANG, Guilin ; URTISHAK, Karen Ann ; HUTNICK, Natalie A ; GORMLEY, Michael P ; LI, Susan Xuemei ; FRANCIS, Peter</creator><creatorcontrib>ZHANG, Ke ; THOMAS, Shibu ; DEL CORRAL, Adam A ; LOPEZ-GITLITZ, Angela Mennicke ; WANG, Guilin ; URTISHAK, Karen Ann ; HUTNICK, Natalie A ; GORMLEY, Michael P ; LI, Susan Xuemei ; FRANCIS, Peter</creatorcontrib><description>The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median radiographic progression-free survival (rPFS).
La présente invention concerne du niraparib et de l'acétate d'abiratérone, plus de la prednisone ou de la prednisolone ; pour une utilisation dans un procédé d'amélioration de l'efficacité du traitement du cancer de la prostate résistant à la castration métastatique (CPRCm) chez un patient présentant des anomalies de réparation de l'ADN, en particulier pour améliorer la survie sans progression radiographique (SSPr) médiane.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230810&DB=EPODOC&CC=WO&NR=2023148345A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230810&DB=EPODOC&CC=WO&NR=2023148345A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ZHANG, Ke</creatorcontrib><creatorcontrib>THOMAS, Shibu</creatorcontrib><creatorcontrib>DEL CORRAL, Adam A</creatorcontrib><creatorcontrib>LOPEZ-GITLITZ, Angela Mennicke</creatorcontrib><creatorcontrib>WANG, Guilin</creatorcontrib><creatorcontrib>URTISHAK, Karen Ann</creatorcontrib><creatorcontrib>HUTNICK, Natalie A</creatorcontrib><creatorcontrib>GORMLEY, Michael P</creatorcontrib><creatorcontrib>LI, Susan Xuemei</creatorcontrib><creatorcontrib>FRANCIS, Peter</creatorcontrib><title>NIRAPARIB AND ABIRATERONE ACETATE PLUS PREDNISONE TO IMPROVE CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HRR ALTERATIONS</title><description>The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median radiographic progression-free survival (rPFS).
La présente invention concerne du niraparib et de l'acétate d'abiratérone, plus de la prednisone ou de la prednisolone ; pour une utilisation dans un procédé d'amélioration de l'efficacité du traitement du cancer de la prostate résistant à la castration métastatique (CPRCm) chez un patient présentant des anomalies de réparation de l'ADN, en particulier pour améliorer la survie sans progression radiographique (SSPr) médiane.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjsGKAkEMROfiQVz_IeB5YHUUvGZilgnMpJvuqEcRaU_LruD-0f6ocfADPFWlKF5qWv2rJIyYpAXUHWDrp3EKyoDE5h5iv88QE-9U8jO3ADLEFA4M1IsKYQ9hbxQGziAKEU1YLcNRrIPBIdk5QkBunC5B68RZPFVzcMjjG0IlTuOKLrn2PmMs549qcj1_38v8pbNq8cVGXV1uv6dyv50v5af8nY5h9blqlutts97gsnmv9QC1HEdF</recordid><startdate>20230810</startdate><enddate>20230810</enddate><creator>ZHANG, Ke</creator><creator>THOMAS, Shibu</creator><creator>DEL CORRAL, Adam A</creator><creator>LOPEZ-GITLITZ, Angela Mennicke</creator><creator>WANG, Guilin</creator><creator>URTISHAK, Karen Ann</creator><creator>HUTNICK, Natalie A</creator><creator>GORMLEY, Michael P</creator><creator>LI, Susan Xuemei</creator><creator>FRANCIS, Peter</creator><scope>EVB</scope></search><sort><creationdate>20230810</creationdate><title>NIRAPARIB AND ABIRATERONE ACETATE PLUS PREDNISONE TO IMPROVE CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HRR ALTERATIONS</title><author>ZHANG, Ke ; THOMAS, Shibu ; DEL CORRAL, Adam A ; LOPEZ-GITLITZ, Angela Mennicke ; WANG, Guilin ; URTISHAK, Karen Ann ; HUTNICK, Natalie A ; GORMLEY, Michael P ; LI, Susan Xuemei ; FRANCIS, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2023148345A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2023</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ZHANG, Ke</creatorcontrib><creatorcontrib>THOMAS, Shibu</creatorcontrib><creatorcontrib>DEL CORRAL, Adam A</creatorcontrib><creatorcontrib>LOPEZ-GITLITZ, Angela Mennicke</creatorcontrib><creatorcontrib>WANG, Guilin</creatorcontrib><creatorcontrib>URTISHAK, Karen Ann</creatorcontrib><creatorcontrib>HUTNICK, Natalie A</creatorcontrib><creatorcontrib>GORMLEY, Michael P</creatorcontrib><creatorcontrib>LI, Susan Xuemei</creatorcontrib><creatorcontrib>FRANCIS, Peter</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ZHANG, Ke</au><au>THOMAS, Shibu</au><au>DEL CORRAL, Adam A</au><au>LOPEZ-GITLITZ, Angela Mennicke</au><au>WANG, Guilin</au><au>URTISHAK, Karen Ann</au><au>HUTNICK, Natalie A</au><au>GORMLEY, Michael P</au><au>LI, Susan Xuemei</au><au>FRANCIS, Peter</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>NIRAPARIB AND ABIRATERONE ACETATE PLUS PREDNISONE TO IMPROVE CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HRR ALTERATIONS</title><date>2023-08-10</date><risdate>2023</risdate><abstract>The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median radiographic progression-free survival (rPFS).
La présente invention concerne du niraparib et de l'acétate d'abiratérone, plus de la prednisone ou de la prednisolone ; pour une utilisation dans un procédé d'amélioration de l'efficacité du traitement du cancer de la prostate résistant à la castration métastatique (CPRCm) chez un patient présentant des anomalies de réparation de l'ADN, en particulier pour améliorer la survie sans progression radiographique (SSPr) médiane.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2023148345A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | NIRAPARIB AND ABIRATERONE ACETATE PLUS PREDNISONE TO IMPROVE CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND HRR ALTERATIONS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T12%3A29%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ZHANG,%20Ke&rft.date=2023-08-10&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2023148345A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |